Vraylar denied by insurance? Appeal and win.
A Vraylar denial is the start of a process, not the end of it. This drug is most often denied because it is a higher-tier brand-name product with no generic equivalent, so plans require prior authorization and frequently demand documented trials of cheaper antipsychotics or antidepressants first. Denials that turn on missing trial history or unmapped plan criteria are frequently overturned when the prescriber documents the diagnosis, the failed prior therapies, and a clear statement of medical necessity.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Vraylar (cariprazine) is an oral atypical antipsychotic approved by the FDA for several conditions. It treats schizophrenia in adults and in patients age 13 and older. It is approved for the acute treatment of manic or mixed episodes of bipolar I disorder in adults and in patients age 10 and older, and for depressive episodes of bipolar I disorder (bipolar depression) in adults. It is also approved as an add-on (adjunctive) therapy alongside an antidepressant for major depressive disorder in adults who have not responded adequately to the antidepressant alone.
Why Vraylar gets denied
- Step therapy not met: the plan requires documented trial and failure, intolerance, or contraindication of one or more preferred antipsychotics (for bipolar or schizophrenia) or a preferred antidepressant regimen (for adjunctive MDD) before it will cover Vraylar.
- Non-formulary or high-tier status: Vraylar has no generic, so many plans place it on a non-preferred or specialty tier and deny it until a formulary or tier exception is filed.
- Prior authorization criteria not documented: the request is missing the specific FDA indication, the ICD-10 diagnosis, or the clinical detail the plan needs to confirm on-label use.
- Off-label or unsupported use: requests for indications not approved by the FDA, or adjunctive MDD use without a documented inadequate response to a standard antidepressant trial, are denied as not medically necessary.
What a winning appeal includes
- The confirmed psychiatric diagnosis with the matching ICD-10 code (for example F31.x for bipolar I disorder, F20.x for schizophrenia, or F32.x/F33.x for major depressive disorder with an antidepressant on board for adjunctive use).
- A documented history of prior medications tried, including drug names, dates, doses, duration, and the specific outcome of failure, intolerance, or contraindication, which directly answers a step-therapy edit.
- A letter of medical necessity that maps the patient's history line by line to the plan's own published coverage criteria and cites the FDA-approved indication being treated.
- Supporting clinical documentation such as chart notes, symptom severity or rating-scale results, prior adverse reactions, and, for adjunctive MDD, evidence of an adequate but inadequate-response antidepressant trial.
How we approach the appeal
First identify which barrier triggered the denial: a formulary or tier issue calls for a formulary exception or tier-exception request, while a step-therapy or clinical denial calls for a prior-authorization appeal supported by a letter of medical necessity. Pull the plan's own written cariprazine policy and quote its criteria back to it, for example its requirement of a documented trial and failure or intolerance of a preferred agent, then show point by point how the patient meets each element. If the written appeal is denied, request a peer-to-peer review between the prescriber and the plan's reviewing physician, and escalate to external (independent) review if the internal appeal fails.
Vraylar appeal letter template
Copy this Vraylar appeal letter, fill in the brackets, and send it within your deadline. It is built on what overturns Atypical antipsychotic denials.
[Date] [Your name] · Member ID [ID] · Rx claim # [#] [Insurer or PBM] - Appeals Department Re: Appeal of Vraylar denial I am appealing the denial of Vraylar (cariprazine). I request that the denial be overturned and Vraylar approved. 1. The denial. [Insurer] denied Vraylar stating, verbatim: "[paste the exact denial reason from your letter]." 2. Medical necessity. Vraylar is medically necessary for my condition. First identify which barrier triggered the denial: a formulary or tier issue calls for a formulary exception or tier-exception request, while a step-therapy or clinical denial calls for a prior-authorization appeal supported by a letter of medical necessity. Pull the plan's own written cariprazine policy and quote its criteria back to it, for example its requirement of a documented trial and failure or intolerance of a preferred agent, then show point by point how the patient meets each element. If the written appeal is denied, request a peer-to-peer review between the prescriber and the plan's reviewing physician, and escalate to external (independent) review if the internal appeal fails. 3. Step-therapy or formulary exception (if that was the reason): I have tried and failed [preferred drug(s)], with pharmacy records attached, or the preferred alternative is contraindicated because [reason]. I request a formulary or step-therapy exception. 4. My request. Approve Vraylar within the timeframe required by law. If the denial is upheld, please provide the specific criteria used, the reviewing clinician's credentials, and external-review instructions. Attached: prescriber letter of medical necessity, pharmacy and prior-trial records, and supporting clinical notes. Sincerely, [Your name]
Want it built and filed for you? Use the free generator, or have Apellica do it.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days of the denial.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Vraylar denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
Why does my insurance want me to try another medication before Vraylar?
Vraylar is a brand-name drug with no generic, so most plans apply step therapy and ask for a documented trial of one or more lower-cost preferred antipsychotics or antidepressants first. If you have already tried and failed, could not tolerate, or have a medical reason to avoid those drugs, your prescriber can document that history to satisfy the step-therapy requirement, and a denial issued without crediting that history can be appealed.
My plan calls Vraylar non-formulary. Can I still get it covered?
Yes. A non-formulary or non-preferred status is not a permanent no. You or your prescriber can file a formulary exception or tier exception arguing that covered alternatives are not appropriate or have failed for you. The plan must give you a written reason for any denial and a way to appeal it, including external review by an independent party.
Vraylar was denied for my depression. Is that appealable?
It can be. Vraylar is FDA approved for major depressive disorder only as an add-on to an antidepressant, so denials often stem from missing documentation that you are on an antidepressant and did not respond adequately to it alone. Supplying that antidepressant trial history, the depression diagnosis with its ICD-10 code, and a letter of medical necessity addresses the most common reason these requests are denied.
Vraylar denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.